Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study ID
NCT06361238
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Delirium, Postoperative

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide injection — DRUG
    Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
  • Placebo injection — DRUG
    Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.

Study Details

This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.

Key Dates

Start date
Nov 19, 2024
Status verified
Dec 2024
Primary completion
Mar 31, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
260 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide Group
    Subcutaneous injection of liraglutide
  • Placebo Comparator: Vehicle Group
    Subcutaneous injection of vehicle

Primary Outcome Measure

The incidence of delirium [ Time Frame: One day before surgery and within the first seven days after surgery. ]

Central Contacts

Related Studies